Remibrutinib NCT07225504 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 3

Clinical phase

Recruiting

Recruitment status

not reported

Planned enrollment

2030-12-03

Primary-completion proxy

Executive view

NCT07225504 evaluates Remibrutinib in Multiple Sclerosis, Secondary Progressive. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is Czechia, United States, Portugal, Greece, Sweden, Netherlands, Latvia, Austria, Ireland, China, Poland, Brazil, Slovenia, Slovakia, Lithuania, France, Bulgaria, Croatia, Colombia, Argentina, Romania, Hungary, United Kingdom, Switzerland, Spain, India, Canada, Belgium, Denmark, South Africa, Mexico, Italy, Israel, Australia, Germany, Estonia. The first listed primary endpoint is Time to 6-month confirmed disability progression (6mCDP) on Expanded Disability Status Scale (EDSS), assessed over From baseline up to approximately 5 years.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07225504 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Multiple Sclerosis, Secondary Progressive landscape. Drug & Asset MCP drug_fetch was queried for Remibrutinib, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07225504	Remibrutinib	Phase 3 / Recruiting	Sponsor not reported	Czechia, United States, Portugal, Greece, Sweden, Netherlands, Latvia, Austria, Ireland, China, Poland, Brazil, Slovenia, Slovakia, Lithuania, France, Bulgaria, Croatia, Colombia, Argentina, Romania, Hungary, United Kingdom, Switzerland, Spain, India, Canada, Belgium, Denmark, South Africa, Mexico, Italy, Israel, Australia, Germany, Estonia	Time to 6-month confirmed disability progression (6mCDP) on Expanded Disability Status Scale (EDSS) From baseline up to approximately 5 years	2030-12-03
NCT07325292	Frexalimab	Phase 3 / Recruiting	Sanofi	Belgium, United States, Japan, China, Brazil, Italy, Spain	Area under the curve over the interval W20 to W24(part A) Until Week 24	2027-07-15
NCT07321093	Ocrelizumab Biosimilar(Biocad)	Phase 3 / Recruiting	Biocad CJSC	Russia	Total number of T1 gadolinium-enhancing (Gd+) lesions up to Week 24. up to Week 24	2028-12-01
NCT07303790	GC-012F	Early Phase 1 / Recruiting	Huazhong University of Science Tongji Hospital, Tongji Medical College	China	Dose-Limiting Toxicity (DLT) Rate 28 days	2027-01-20
NCT07299019	Orelabrutinib	Phase 3 / Recruiting	Zenas BioPharma LLC.	United States, Hungary, Czechia, Poland, Italy, Serbia, Lithuania, Bulgaria, Estonia, Croatia	Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks Up to approximately 120 weeks	2030-06-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07225504 is a Phase 3, recruiting study with not reported planned participants. Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment.

The primary endpoint is “Time to 6-month confirmed disability progression (6mCDP) on Expanded Disability Status Scale (EDSS)” over “From baseline up to approximately 5 years.” The retrieved endpoint description is: The EDSS is an ordinal scale used for assessing neurologic impairment in MS based on a neurological examination. It consists of scores in each of seven functional systems and an ambulation score that are then combined to determine the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). 6mCDP is defined as an increase from baseline in EDSS sustained for at least 6 months..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

The protocol identifies Remibrutinib as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Multiple Sclerosis, Secondary Progressive. These records do not establish direct evidence for NCT07225504 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Remibrutinib is indexed as Small molecule drug with BTK biology and a global stage of Approved. The asset profile lists Novartis Pharma AG as an originator or developer.

No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Remibrutinib is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07225504
Protocol source: https://clinicaltrials.gov/study/NCT07225504
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

Remibrutinib in Multiple Sclerosis, Secondary Progressive is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Time to 6-month confirmed disability progression (6mCDP) on Expanded Disability Status Scale (EDSS) and 2030-12-03 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP